NCOA3 and breast carcinoma: The constructs were subsequently applied to imaging the action of ER agonists and antagonists in living subjects (Figure 2A; [52]), and are thought to offer much potential for screening novel breast cancer therapeutics, particularly those that target ERα-coactivator/AIB1 interaction.